INTRODUCTION
Exosomes, small membrane vesicles (30-100 nm) with a cup-shaped morphology, are of endosomal origin. Exosomes represent the smallest of the extracellular vesicles (EVs), which are released by cells and differentiated with regards to size into large, medium and small [1] (Figure 1 ). Their formation begins with the invagination of the cell membrane to form endosomes, followed by the creation of multivesicular bodies (MVBs) ( Figure 2 ). The fusion of MVBs with the plasma membrane releases the internal vesicles, called exosomes [2] [3] [4] . Studies indicate that exosomes can be released by nearly all living cells in the body, including stem cells, platelets, cardiomyocytes, endothelial cells, dendritic cells, B lymphocytes, and tumor cell lines, among others [5] [6] [7] [8] [9] [10] . Exosomes contain cargo, including functional microRNAs/RNAs, proteins and lipids, which they deliver to other cells, providing means for a new way of cell-to-cell communication [11] [12] [13] [14] . Components present in exosomes can also help modify the functions of different The role of tumor-derived exosomes in tumor angiogenesis and tumor progression Current Issues in Pharmacy and Medical Sciences
MECHANISM OF ANGIOGENESIS/VASCULATURE IN TUMOR MICROENVIRONMENT
Angiogenesis and lymphangiogenesis are the processes where new blood and lymphatic vessels, respectively, are formed. Neovascularization, involving tumor angiogenesis, consists of the following steps: protease production, endothelial cell proliferation and migration, vascular tube formation, anastomosis of newly formed tubes, synthesis of a new basement membrane, and incorporation of pericytes and smooth muscle cells. In the first step, the tissue basement membrane is locally destroyed by proteases, which immediately creates a hypoxic environment. Angiogenic factors start to activate endothelial cells (ECs) to migrate. After the activation of ECs by angiogenic stimuli, proteolytic enzymes are produced, that degrade the perivascular extracellular matrix (ECM) and the rest of the basement membrane. Subsequently, the ECs proliferate and migrate into the perivascular area, forming "primary sprouts", followed by the synthesis of a new basement membrane, tube-like structures formation, blood vessel maturation and complete capillary loops, through which blood can flow [21] [22] [23] .
The new vasculature in the tumor microenvironment is structurally and functionally abnormal compared to normal blood vessels [21] , which contributes to the heterogeneity in tumor blood flow. The tumor blood vessels are immature and leaky [24] , characterized by smaller diameter [24] [25] [26] [27] , more permeability [24, [26] [27] [28] with lack of or a detached pericyte and basement membrane [24, 26, 29] , heterogeneous vascular density [24] [25] [26] , and nearly equal microvascular and interstitial fluid pressure [24, 28, 30] . In addition, fast proliferating cancer cells compress intratumoral blood and lymphatic vessels, and as a result, generate pressure and lead to abnormalities in the microenvironment such as impaired blood supply, interstitial hypertension, hypoxia and acidosis [31] .
ANGIOGENIC FACTORS
Vascular endothelial cells divide about every 1000 days on average [32] . In growing cancers, endothelial cells are vigorously active because of the release of many angiogenic factors [22] . Angiogenesis is regulated by both activator and inhibitor molecules. However, angiogenesis in neoplasms is characterized by both up-regulation of the activators as well as down-regulation of the negative regulators of vessel growth [33] . Stimulating factors involve proteins, such as epidermal growth factor (EGF), estrogen, basic and acidic fibroblast growth factor (FGF), interleukin 8 (IL-8), prostaglandin E1 and E2, tumor necrosis factor α (TNF-α), angiogenin, transforming growth factor (TGF-α), TGF-β, platelet-derived endothelial growth factor (PDGF), granulocyte colony-stimulating factor (G-CSF), placental growth factor (PGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF), which can activate ECs growth and motility. VEGF and bFGF are particularly important in tumor angiogenesis [21, 22] .
The VEGF family and their receptors (VEGFR) are powerful angiogenic agents in neoplastic tissues, as well as in normal tissues [34] [35] [36] . Some angiogenic states can be triggered by hypoxia resulting from the increasing distance between the growing tumor cells and the host capillaries or from the inefficiency of new vessels. Hypoxia induces the expression of VEGF and its receptor via hypoxia-inducible factor-1α (HIF-1α) [37] . The binding of VEGF to its receptor activates proteins relay, that transmit a signal into the nucleus of the endothelial cell. The nuclear signal prompts a group of genes to manufacture the products required for new endothelial cell growth. ECs activated by VEGF produce matrix metalloproteinases (MMPs). The MMPs break down the ECM that fills the spaces between cells and is made up of proteins and polysaccharides. This matrix permits the migration of ECs. The ECs begin to divide as they migrate into the surrounding tissues. Soon they organize themselves into hollow tubes that evolve gradually into a mature network of blood vessels with the help of an adhesion factor, such as integrin α or β [38, 39] . Newly formed blood vessels need to be stabilized to mature. Angiotensin-1, -2, and their receptor Tie-2 can stabilize and govern vascular growth [40] [41] [42] .
On the immunohistochemical examination, the VEGF family and their receptors were found to be expressed in about half of the investigated human cancers [43] . These studies also indicated, that the levels of angiogenic factors in tissue reflect the aggressiveness with which tumor cells spread, and thus have a predictive value in the identification of high-risk patients with poor prognosis [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] . It was also reported that physiological concentrations of thyroid hormone are pro-angiogenic by multiple mechanisms. This increases the possibility that the thyroid hormone (thyroxine) is a case of a non-protein stimulator of angiogenesis that may contribute to clinical resistance to anti-angiogenesis drugs [64] . Prostaglandin E2 (PGE2), as a mitogen in epithelial tumor cells, is another example of a non-protein stimulator of angiogenesis in the vascular endothelium. It has been also shown that the overexpression of cyclooxygenase-2 (an enzyme for the conversion of arachidonic acid to prostaglandin H2) is accompanied by enhanced expression and production of angiogenic factors such as VEGF, FGF-2, HIF-1, MMPs, and adhesion receptors of the integrin families. Therefore, it has been determined, that a high output of PGE2 via increased expression of cyclooxygenase-2, causes tumor development [65, 66] . Furthermore, the CCN family of matricellular proteins are cytokines linking cells to the extracellular matrix. CCN3 is pro-angiogenic, while CCN5 is anti-angiogenic [67] [68] [69] [70] . Multimerin 2 (MMRN2) has anti-angiogenic potential, and its downmodulation occurs in the context of tumor-associated angiogenesis [71, 72] .
There are many naturally occurring proteins, that can inhibit angiogenesis [21] . These signals may systematically disrupt blood vessel formation or support the removal of existing vessels. Inhibitors function by acting on several proteins, that have been identified as angiogenic activators [22] . For angiogenesis to proceed, the functions of negative regulators of vessel growth may need to be down-regulated [21] . The inhibitors include naturally occurring factors such as angiostatin, endostatin, interferon, platelet factor 4, thrombospondin, prolactin 16 kd fragment, tissue inhibitor of metalloproteinase-1, -2, and -3, interleukin 1 and interleukin 12, and retinoic acid [73] [74] [75] . Angiostatin is composed of one or more fragments of plasminogen [76] . It induces apoptosis in ECs and tumor cells, and inhibits migration, and formation of tubules in ECs [77, 78] . Immunohistochemical examination of angiostatin-treated tumors indicated a decrease in the expression of mRNA for VEGF and bFGF [79] . Endostatin binds to the receptor in ECs and may block ECs focal adhesion [80, 81] . Endostatin also inhibits growth factors (e.g., bFGF and VEGF-A), and induces proliferation and migration of endothelial cells in vitro and in vivo [82] [83] [84] .
TUMOR MICROENVIRONMENT PROMOTING AN-GIOGENESIS VIA EXOSOMES
It is well known that angiogenesis is regulated by oxygen supply and stimulated when tumor tissues require the nutrients and oxygen, that are provided by blood vessels [21, 22] . Oxygen is the key to cell growth or local metastasis, and its level correlates with the metabolism of endothelial or cancer cells [85, 86] . Oxygen pressure in normal cells is about 40-60 mmHg, as opposed to the majority of malignancies, where the level is about 10 mmHg [87] . Oxygen deprivation in the TME is the result of low supply, because of the distance from supporting blood vessels, irregular tumor vascularization and the increasingly high demand from proliferating cancer cells [88, 89] . This condition of insufficient oxygen supply, called hypoxia, characterizes malignant tumors, and is involved in their aggressiveness and metastasis [90, 91] . To monitor oxygen supply, various oxygen-sensing mechanisms are present in ECs and smooth muscle cells (SMCs), such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, endothelial nitric oxide synthases (eNOS), and heme-oxygenases [92] . Other oxygen sensors expressed in vascular cells are hypoxiainducible transcription factors (HIFs), the major components of hypoxia signaling pathways [93] .
In response to oxygen insufficiency, cancer cells modify the transcription of genes connected with oxygen monitoring mechanisms, especially HIFs [93] . Almost all types of cancer are characterized by the activation of HIFs. HIFs are present in 3 isoforms of the oxygen-sensitive HIF-α (HIF-1α, HIF-2α, or HIF-3α), and a constitutively expressed HIF-1β subunit [94, 95] . The response to hypoxic conditions is through the activation of HIF-dependent signaling pathways, that regulate the expression of genes associated with angiogenesis, epithelial-to-mesenchymal transition (EMT), metastasis and cellular adaptation for survival in hypoxic conditions [96] . Hypoxia also induces an increased release of exosomes from oxygen-deprived tumor cells, in comparison to cells in normoxic conditions, especially in the context of long-term hypoxia [97] . Studies showed, that moderate (1% O 2 ) and severe (0.1% O 2 ) hypoxia lead to a significant increase in the number of exosomes, as observed in three different breast cancer cell lines [98] . In addition to the quantitative impact of exosome secretion, hypoxia-induced stress also causes significant changes in the content and function of exosomes [99] . Exosomes also play a major role in the communication between hypoxic tumors and their microenvironments [18] . Hypoxia-induced exosomes cross-talk with surrounding stromal tissues and transfer tumor phenotypes promoting tumor angiogenesis, invasion, metastasis and immune escape [99] .
In the context of angiogenesis, hypoxia is a major inductor [18] . Hypoxic exosomes, by alterations in their molecular cargo, modulate tumor-ECs communication, inducing ECs proliferation and tube formation [18] (Figure 3 ). The expression of different non-coding RNAs delivered by exosomes, such as miR-210, miR135b, miR23a, miR494, is regulated Hypoxic condition in the tumor environment increases the release of tumorderived exosomes (TEX) and is a strong stimuli for the communication between cancer and endothelial cells (ECs). TEX transfer molecular information, which after uptake by ECs, promote their adhesion, proliferation, migration, tube formation, and as a result pathological angiogenesis [20] (modified) Figure 3 . Cancer and endothelial cells cross-talk Current Issues in Pharmacy and Medical Sciences by hypoxia [99] . Research has shown that hypoxic exosomes with miR-210 were released from breast cancer in significant quantities through HIF-1α activation [98] . Hypoxia induces neutral sphingomyelinase2 (nSMase2), mediating mRNA sorting in exosomes, and leads to the secretion of miR-210, which plays a role in angiogenesis [100] . In vitro studies present tube formation in human umbilical vein endothelial cells (HUVECs) incubated with hypoxic exosomes rich in miR-210 and released from human leukemic cells [101] . In another study, expression of exosomal miR-135b was significantly higher in hypoxia-resistant multiple myeloma (HR-MM) as compared to normoxic cells [102] . Moreover, this exosomal miR-135b was captured by ECs and enhanced angiogenesis via HIF-1 activation [102] .
Targeting prolyl hydroxylase and tight junction protein ZO-1 by exosomal miR23a derived from hypoxic lung cancer cells also stimulates angiogenesis [103] . In exosomal cargo derived from hypoxic lung cancer cells, miR-494 was highly expressed via the HIF-1α-mediated mechanism, following capture by ECs, which in turn down-regulated PTEN and activated the Akt/eNOS pathway [104] . Furthermore, in exosomes released from hypoxic human squamous carcinoma cells, A431 was found to facilitate angiogenesis [105] , while hypoxic glioblastoma exosomes were enriched with VEGF [106] [107] [108] [109] [110] . Furthermore, hypoxic colorectal cancer exosomes were found to stimulate the proliferation of ECs [111] . Moreover, hypoxic hepatocellular carcinoma [112] , and breast cancer cells were seen to induce angiogenesis in vitro and in vivo via miR-23a and miR-210, respectively, while enclosed in their exosomes [98] . In addition, exosomes originating from hypoxic brain tumor glioblastoma multiforme cells were noted to present increased levels of IL-8 and PDGF as angiogenic stimulatory molecules [108] .
EVs produced by hypoxic tumor cells have been shown to have a more pronounced effect on ECs in promoting angiogenesis than those derived from normoxic cells [102, 113] . Hypoxia increases the production of tumor and stromal cell-derived EVs, and alters their cargo [98, 102, 103, 114, 115] . For example, miR-23a is found in the EVs of hypoxic, but not normoxic, lung cancer cells [103] . Increased EVs production by hypoxic endothelial cells was abrogated by siRNA targeting hypoxia-inducible factor 1, thus providing a clear link between cell response to hypoxia and EVs production [114] .
The tumor microenvironment consists of cellular and acellular factors and includes ECM, cancer-associated fibroblasts (CAFs), inflammatory immune cells and tumorassociated vasculature [116] . CAFs are important components within the TME that play a key role in tumorigenesis. Analysis with mass spectrometry has identified a plethora of growth factors released by CAFs-derived exosomes such as modulators of epidermal growth factor receptor (EGFR), insulin-like growth factor receptor (IGFR), platelet-derived growth factor receptor (PDGFR), chemokines, cytokines, and matrix metalloproteinases. These factors remodel the ECM significantly and contribute to important hallmarks necessary for cancer progression, such as sustained growth, invasion, inflammation, angiogenesis, metastasis and therapeutic resistance [117] [118] [119] . Furthermore, studies demonstrate a correlation between hypoxic conditions and the activation of CAFs-prostate cancer cells with an insufficient oxygen supply, that released exosomes containing nearly three times more protein than that in normoxic conditions, resulting in CAFs induction [120] , promotion of EMT, stemness, and angiogenesis [121, 122] .
MOLECULAR CARGO OF TEX INFLUENCING ANGIOGENESIS / TEX CONVERTING ENDOTHELIAL CELLS
Endothelial cells belonging to the tumor microenvironment are key components providing a conduit to nutrients, and represent a source of trophic factors [123] . Angiogenesis, a complex and multistep process, consists of proliferation, migration, invasion, adhesion and differentiation of ECs [124] . Various physiological and pathological conditions [125] stimulating vascularization, following tumor growth and metastasis [126] , are regulated via the transfer of pro-angiogenic molecules from tumor to endothelial cells by EVs (Figure 2) . In a variety of cancer types, EVs have been shown to increase tube formation, migration, cell-cell adhesion and proliferation in ECs [100, 102, 113, [127] [128] [129] [130] [131] [132] [133] . Studies have been performed to determine the relationship between EVs and pathological angiogenesis [134] . It was demonstrated that HUVECs induce pathological angiogenesis [135] via an abundance of genetic information transferred by EVs [136] . In response to TEX uptake by HUVECs, tube formation, proliferation, migration and adherence were observed. TEX were investigated to have the potential to reprogram and induce phenotypic modulation of ECs. Studies indicated that HUVECs internalize TEX carrying angiogenic proteins within 4 hours, stimulating their conversion into vascular structures in vitro [20] . The same results were achieved in in vitro studies with exosomes derived from metastatic tumor cells [100] . Moreover, EVs from nasopharyngeal carcinoma (NPC) cells are enriched with HCLS1-associated protein X-1 (HAX-1) and could accelerate the proliferation and migration of HUVECs [134] .
Exosomes also play an instrumental role in tumor-ECs communication [123] . The EVs from tumor cells contain various pro-angiogenic molecules, such as bFGF, VEGF and TGF-β, that function as stimuli for endothelial cell proliferation and migration [137, 138] . Activated EGFR found in EVs is sufficient to induce EGFR and VEGFR signaling in recipient endothelial cells [128, 139] . ECs incorporated TEX with cargo such as tetraspanin 8, CD106, and activated VEGFs, resulting in ECs proliferation, migration, sprouting and maturation of ECs progenitors [140] . The endothelial progenitor cells release exosomes that interact with mature ECs, and integration of their cargos trigger AKT signaling, resulting in angiogenesis [141] . Tetraspanins were discussed for their role in exosome biogenesis, cargo sorting, cancer progression, and are suggested to be key players in the process of angiogenesis [142] . Exosomes derived from myeloma and breast cancers demonstrate the presence of Syndecan-1, VEGF and HGF, which lead to increased endothelial invasion through the ECM [143] . Melanoma-derived exosomes were also shown to produce angiogenic growth factors [144] .
With the aid of exosomes derived from glioma cells, the oncogenic receptor EGFRvIII was transported. This resulted in EGFRvIII-dependent transcription, transforming phenotype and oncogenic activity [139] . Additionally, by delivering Epidermal Growth Factor Receptor (EGFR) [128] and miR-9 to ECs [145] , skin cancer-derived exosomes can promote angiogenesis. Exosomes originated from melanoma cells, including miR-9, enhance angiogenesis and metastasis via activation of the JAK-STAT pathway after internalization by ECs [145] . Increased vascularization has been associated with the packaging of CO-029/D6. 1A Tetraspanin in pancreatic cancer-derived exosomes [142] , and of miR-92a in leukemia-derived exosomes which can regulate integrin 5 to promote migration and proliferation of ECs and tube formation [146] . Other EV-derived molecules that have been shown to play a role in promoting angiogenesis include miR-105, miR-142-3p, miR-210 and H19 lncRNA [103, [129] [130] [131] 133, 147, 148] .
The integrity of vascular barriers is frequently associated with metastatic dissemination. TEX carrying miR-105 are known to destroy vascular endothelial barriers by targeting the tight junctions of ECs and modifying the expression of claudin 5, zonula occludens protein 1, and occludin, thereby promoting metastasis in breast cancer [147] . Brain tumor-derived exosomes containing miR-181c modulate actin in ECs and promote the breakdown of the blood-brain barrier by 3-phosphoinositide-dependent protein kinase-1 degradation [149] . Similarly, exosomes produced by glioblastoma cells containing high levels of VEGF-A induce ECs permeability and angiogenesis in vitro [150] . In the same way, melanoma-derived exosomes induce pulmonary vascular leakiness [151] , and upregulate genes related to the tumor cell recruitment, such as stabilin 1, vitronectin, integrins, and ephrin receptor b4 in lymph nodes [144] .
Exosomal miR-21 and 29a can act as ligands for toll-like receptors and can induce inflammatory responses during pre-metastatic niche formation [101] . Pre-metastatic niche formation contributes to the metastasis, where progenitors have shown an increased expression of VEGF-1 in target sites and overexpression of fibronectin in resident fibroblast [152] .
Another report uncovered the fact that CD-105-positive exosomes possess an important role in establishing a niche in the lung microenvironment of SCID mice through the increased expression of MMP2, MMP9, and VEGFR1 [113] . This suggests there are sub-populations with cell markers indicative of tumor-initiating cells. In related work, the impact of the heterogeneity found within tumors was investigated. In renal cell carcinoma cell lines, CD105-positive cells were found to release EVs that increase proliferation, vessel formation, and invasion in HUVECs, whereas CD105-negative cells did not [113] . Similarly, in liver cancer cells, CD90-positive cells were found to secrete EVs, that promote tube formation and cell-cell adhesion via the transfer of H19 lncRNA [129] . These results suggest, that subsets of tumor cells secrete EVs carrying a unique set of cargo capable of altering stromal cell phenotypes in specific ways [153] .
EMT promotion, together with degradation of ECM and cell adhesion junctions between adjacent cells, is conducted by activation of plasminogen and its conversion into plasmin, as triggered by exosomal hsp90, along with annexin-II released to the extracellular sites [154] . Communication between metastatic tumor cells and ECs can activate various cytoskeletal proteins such as RAC1, which regulate endothelial tubular morphology by inducing tubular sprouting and spheroid formation [155, 156] . Genes related to vascular remodeling, such as ephrin A3 and PTP1B were also reported to be expressed and transferred via exosomes [18] .
POTENTIAL OF TEX AS NEW TARGETS IN CANCER
In general, inhibitors of angiogenesis can be classified into two main groups: direct inhibitors, that target endothelial cells in the growing vasculature, and indirect inhibitors, that target either tumor cells or the other tumor-associated stromal cells [157] .
Cytotoxic therapy suppresses cancer directly, while angiogenic therapy suppresses it indirectly by depriving cells of nutrients and oxygen. The use of angiogenesissuppressors and receptor-inhibitors can prohibit the neovascularization of cancer tissue, as well as the growth of the tumor, and thus might be beneficial in the treatment of cancer [21] . During tumor progression, the anti-angiogenic factors' production is reduced, with a simultaneous elevation of pro-angiogenic factors. This helps explain the current suboptimal effectiveness in the oncology of the pharmacological inhibitors of single endogenous angiogenic agents [22] . Moreover, evidence supports the view, that cytotoxic agents and anti-angiogenic agents would destroy both cancer cells and endothelial cells [158] . Abnormal microenvironments characterized by impaired blood supply, interstitial hypertension, hypoxia, and acidosis [31] interfere with the delivery of therapeutic drugs, rendering tumor cells resistant to both radiation and some forms of cytotoxic therapy. These conditions also result in genetic stability and selection for more malignant cells with increased metastatic potential, and compromise the cytotoxic functions of immune cells. This emphasizes the importance of normalizing and regulating tumor vasculature [21] . The adverse reactions of the inhibition of VEGF therapy is decreased production of NO, which will promote vasoconstriction, increase the peripheral resistance, and eventually elevate blood pressure [159] . Under normal conditions, VEGF is known to release vasodilator nitric oxide (NO) in vessel walls by upregulating endothelial nitric oxide synthase and prostacyclin (PGI2), resulting in vasodilation, through the activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) downstream pathways [160] [161] [162] [163] .
The data suggest that TEX promote angiogenesis and drive cancer progression [20] . At the same time, exosomes can be used for drug targeting [18] . Future efforts should focus on eliminating or silencing TEX and thereby adding new options for improving existing anti-angiogenic therapies [20] . Recent approaches involve counteracting the pro-tumorigenic effects of EVs. One of them is to directly remove EVs from circulation. This was conducted by Marleau [164] , by using an extracorporeal hemofiltration system to filter blood for components under 200 nm and then removing them by means of applying affinity agents Current Issues in Pharmacy and Medical Sciences for target molecules. In another investigation, the treatment of mice with anti-CD9 or anti-CD63 antibodies was found to stimulate EVs removal by macrophages, thus greatly decreasing EVs concentration in the blood. Although this treatment had no effect on the primary tumor, the authors observed a significant reduction in metastasis [165] . Blocking EVs biogenesis in tumor cells by silencing genes encoding EV-related machinery is another potential avenue for inhibiting tumorigenesis [130, 147, 166] .
Exosomes can be also engineered to transport a variety of molecules like protein, peptides, drugs, etc. even across the blood-brain barrier without inducing any systemic toxic effects, making them promising candidates for drug delivery. Exosomes have been used for the delivery of various chemotherapeutics and also natural substances like curcumin, resveratrol, etc. Similarly, nanoformulations of other natural drug candidates against pro-angiogenic factors may provide selective inhibition and might also be a promising option [167] .
CONCLUSION
While elaborating on tumor progression, which is tightly connected with neoplastic vascularisation, we have to take into consideration the presence of TEX in TME. The release of tumor -as well as stromal cell-derived exosomes increases in hypoxic conditions, thereby initiating and promoting the angiogenesis process.
Hypoxia-induced TEX cross-talk with surrounding stromal tissues results in the transfer of tumor phenotypes, which, as a consequence, results in tumor angiogenesis, invasion, metastasis and immune escape. In the context of angiogenesis, by the alteration in their molecular cargo, hypoxic TEX reprogram ECs and induce phenotypic modulation of ECs. As a result, increased migration, cell-cell adhesion, proliferation of ECs, and enhanced tubular sprouting, and tube formation is observed. The potential of TEX, as angiogenesis process inducers, make them a target in antiangiogenic therapy. The conducted attempts of eliminating or silencing TEX have resulted in a significant reduction in metastasis. Blocking TEX biogenesis is another potential in decreasing their negative role. Being natural cell transport vehicles, exosomes can be also engineered to transport a variety of molecules, making them promising candidates for drug delivery. These findings provide new insights into the complex cellular and genomic networks and can give new perceptivity into improving existing anti-angiogenic therapies.
LIST OF ABBREVIATIONS
Mini-SEC -mini size exclusion chromatography; CCN -family of regulatory proteins (Connective tissue growth factor (CTGF), Cystein rich protein (Cyr61) and Nephroblastoma overexpressed gene (nov)); PTEN -phosphatase and tensin homolog deleted on chromosome ten; SCID mice -severe combined immunodeficiency mice.
